Application of Quantitative Motor Assessments in Friedreich Ataxia and Evaluation of Their Relation to Clinical Measures.


Journal

Cerebellum (London, England)
ISSN: 1473-4230
Titre abrégé: Cerebellum
Pays: United States
ID NLM: 101089443

Informations de publication

Date de publication:
Oct 2019
Historique:
pubmed: 24 8 2019
medline: 4 3 2020
entrez: 24 8 2019
Statut: ppublish

Résumé

Friedreich's ataxia (FRDA) is a rare autosomal-recessive slowly progressive neurodegenerative disorder. As common clinical measures for this devastating disease lack sensitivity, we explored whether (a) the quantitative motor assessments of the Q-Motor battery can enhance clinical characterisation of FRDA; (b) clinical measures can predict Q-Motor outcomes and (c) Q-Motor is sensitive to longitudinal change. At baseline 29 patients and 23 controls and in a 1-year follow-up 14 patients and 6 controls were included. The Q-Motor included lift (manumotography), finger tapping (digitomotography) and pronate/supinate (dysdiadochomotography) tasks. To model responses, a search of generalised linear models was conducted, selecting best fitting models, using demographic and clinical data as predictors. Predictors from selected models were used in linear mixed models to investigate longitudinal changes. Patients with FRDA performed worse than controls on most measures. Modelling of the pronate/supinate task was dominated by SCAFI (SCA functional index) subtasks, while tapping task and lift task models suggested a complex relationship with clinical measures. Longitudinal modelling implied minor changes from baseline to follow-up, while clinical scales mainly showed no change in this sample. Overall Q-Motor likely has favourable properties for assessing distinct motor aspects in severe FRDA as it can be administered in wheelchair-bound patients. Further longitudinal research is warranted to fully characterise its relation to routinely used measures and scales for FRDA.

Identifiants

pubmed: 31441004
doi: 10.1007/s12311-019-01073-x
pii: 10.1007/s12311-019-01073-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

896-909

Subventions

Organisme : Bundesministerium für Bildung und Forschung
ID : BMBF 01GQ1402

Références

Exp Neurol. 2000 May;163(1):136-48
pubmed: 10785452
Neurology. 2001 Sep 11;57(5):920-4
pubmed: 11552034
Hum Mov Sci. 2003 Apr;22(2):189-205
pubmed: 12667749
Neurology. 2006 Jun 13;66(11):1717-20
pubmed: 16769946
Motor Control. 2008 Jan;12(1):3-20
pubmed: 18209246
Brain. 2008 May;131(Pt 5):1352-61
pubmed: 18378516
Neurology. 2008 Aug 12;71(7):486-92
pubmed: 18695159
Eur J Neurol. 2009 Feb;16(2):232-9
pubmed: 19146643
J Neurol. 2009 Mar;256 Suppl 1:3-8
pubmed: 19283344
J Neurol. 2010 Apr;257(4):518-23
pubmed: 19823893
Biometrics. 1946 Dec;2(6):110-4
pubmed: 20287815
Mov Disord. 2010 Dec 15;25(16):2858-62
pubmed: 20818671
Neurobiol Dis. 2011 Feb;41(2):560-9
pubmed: 21059390
Neurology. 2010 Dec 14;75(24):2150-60
pubmed: 21068430
Hum Brain Mapp. 2012 Jan;33(1):203-12
pubmed: 21264990
Hum Brain Mapp. 2013 Mar;34(3):519-29
pubmed: 22102212
J Child Neurol. 2012 Sep;27(9):1133-7
pubmed: 22752493
J Neurol. 2013 Feb;260(2):407-14
pubmed: 22872165
Cerebellum. 2013 Jun;12(3):418-28
pubmed: 23090211
Lancet Neurol. 2013 Jul;12(7):637-49
pubmed: 23664844
J Neurochem. 2013 Aug;126 Suppl 1:11-20
pubmed: 23859338
Oxid Med Cell Longev. 2013;2013:487534
pubmed: 23936609
Mov Disord. 2014 Nov;29(13):1648-54
pubmed: 25123926
Lancet Neurol. 2015 Feb;14(2):174-82
pubmed: 25566998
Mov Disord. 2015 Mar;30(3):427-31
pubmed: 25689146
J Neural Transm (Vienna). 2015 Sep;122(9):1271-8
pubmed: 25712401
PLoS One. 2015 Mar 18;10(3):e0119376
pubmed: 25785588
J Neuroeng Rehabil. 2015 Apr 23;12:41
pubmed: 25900021
PLoS One. 2015 Apr 22;10(4):e0123914
pubmed: 25902182
PLoS One. 2015 Jul 17;10(7):e0132983
pubmed: 26186225
BMC Neurol. 2015 Oct 08;15:190
pubmed: 26450403
BMC Neurol. 2015 Dec 23;15:265
pubmed: 26701600
Lancet Neurol. 2016 Dec;15(13):1346-1354
pubmed: 27839651
J Neuropathol Exp Neurol. 2017 Feb 1;76(2):101-108
pubmed: 28082326
Cerebellum Ataxias. 2017 Apr 7;4:4
pubmed: 28405347
J R Soc Interface. 2017 Sep;14(134):
pubmed: 28904005
Handb Clin Neurol. 2017;144:209-225
pubmed: 28947119
J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):559-565
pubmed: 29279305
J Neurol Neurosurg Psychiatry. 2019 May;90(5):615-617
pubmed: 29945881
Neurology. 2018 Sep 4;91(10):e917-e930
pubmed: 30097477
Dement Geriatr Cogn Disord. 2018;46(3-4):168-179
pubmed: 30257254
Neuropsychologia. 1971 Mar;9(1):97-113
pubmed: 5146491
Science. 1996 Mar 8;271(5254):1423-7
pubmed: 8596916

Auteurs

Christian Hohenfeld (C)

Department of Neurology, RWTH Aachen University, Pauwelsstraße 30, 52074, Aachen, Germany.
JARA-Brain Institute Molecular Neuroscience and Neuroimaging, Forschungszentrum Jülich GmbH/RWTH Aachen University, Aachen, Germany.

Imis Dogan (I)

Department of Neurology, RWTH Aachen University, Pauwelsstraße 30, 52074, Aachen, Germany.
JARA-Brain Institute Molecular Neuroscience and Neuroimaging, Forschungszentrum Jülich GmbH/RWTH Aachen University, Aachen, Germany.

Robin Schubert (R)

George-Huntington-Institute, Technology-Park, Münster, Germany.

Claire Didszun (C)

Department of Neurology, RWTH Aachen University, Pauwelsstraße 30, 52074, Aachen, Germany.
JARA-Brain Institute Molecular Neuroscience and Neuroimaging, Forschungszentrum Jülich GmbH/RWTH Aachen University, Aachen, Germany.

Ludger Schöls (L)

Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
German Centre for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

Matthis Synofzik (M)

Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
German Centre for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

Ilaria A Giordano (IA)

Department of Neurology, University Hospital Bonn, Bonn, Germany.
German Centre for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Thomas Klockgether (T)

Department of Neurology, University Hospital Bonn, Bonn, Germany.
German Centre for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Jörg B Schulz (JB)

Department of Neurology, RWTH Aachen University, Pauwelsstraße 30, 52074, Aachen, Germany.
JARA-Brain Institute Molecular Neuroscience and Neuroimaging, Forschungszentrum Jülich GmbH/RWTH Aachen University, Aachen, Germany.

Ralf Reilmann (R)

George-Huntington-Institute, Technology-Park, Münster, Germany.
Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Department of Clinical Radiology, University of Münster, Münster, Germany.

Kathrin Reetz (K)

Department of Neurology, RWTH Aachen University, Pauwelsstraße 30, 52074, Aachen, Germany. kreetz@ukaachen.de.
JARA-Brain Institute Molecular Neuroscience and Neuroimaging, Forschungszentrum Jülich GmbH/RWTH Aachen University, Aachen, Germany. kreetz@ukaachen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH